Page 2 - Gsk Pharma
GSK in quest to be best, not first, in race for coronavirus vaccine
GSK, which is in seven collaborations with institutions or firms globally, only entered the clinical trial stage with one project on Friday
 "GSK in quest to be best, not first, in race for coronavirus vaccine")
GSK to produce 1 billion doses of coronavirus vaccine booster in 2021
The British drugmaker is working on its own COVID vaccine with Sanofi
 "GSK to produce 1 billion doses of coronavirus vaccine booster in 2021")
GSK Pharma: Near term headwinds may keep stock prices under pressure
April sales were the worst among top drug players
 "GSK Pharma: Near term headwinds may keep stock prices under pressure")
Weak financials, impairment charge ail GSK Pharma; stock falls over 12%
Trading at 41x its FY21 earnings, most analysts have 'sell' rating
 "Weak financials, impairment charge ail GSK Pharma; stock falls over 12%")
Pfizer planning initial public offering of GSK consumer venture in four yrs
Albert Bourla, CEO of Pfizer, discussed the time frame for the IPO at the JPMorgan Healthcare Conference in San Francisco on Tuesday
 "Pfizer planning initial public offering of GSK consumer venture in four yrs")
Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf
Repositioning an old brand helps expand the footprint, say analysts
 "Legacy pharma brands spin gold for GSK, Pfizer; keep newcomers off the turf")
GSK's HIV venture fails to get USFDA approval for once-a-month injection
ViiV Healthcare received a complete response letter from the Food and Drug Administration, which cited "chemistry manufacturing and controls," according to a statement from the HIV unit
Crocin 2.0: GSK is reinventing the pain-reliever brand to keep it relevant
The British multinational adds a fresh extension to its 40-year-old flagship, hopes to leverage the brand's recall to expand its remedial reach
 "Crocin 2.0: GSK is reinventing the pain-reliever brand to keep it relevant")
GSK gains 38% over 3 months, gets boost from tighter low-end portfolio
Revenue growth, margins have been trending up over the past couple of quarters
 "GSK gains 38% over 3 months, gets boost from tighter low-end portfolio")
As price pressure mounts, pharma companies tap analytics to cut costs
Cipla is the first company in the Asia Pacific to upgrade to a cloud-based pharmacovigilance solution
 "As price pressure mounts, pharma companies tap analytics to cut costs")
GSK Pharma's health gets boost from focus on top brands' yields
The company is focusing completely on promoting its top twenty brands, including the antibiotic Augmentin, and antipyretic Calpol
 "GSK Pharma's health gets boost from focus on top brands' yields")
Price revisions, new products should add to GSK Pharma's top-line growth
Brands, vaccines to drive margins for GSK Pharma
 "Price revisions, new products should add to GSK Pharma's top-line growth")
GSK Pharma's September-quarter profit down 23% to Rs 1.01 billion
The company had posted a net profit of Rs 130.32 crore in the year-ago period, GSK Pharma said in a BSE filing
 "GSK Pharma's September-quarter profit down 23% to Rs 1.01 billion")
GST impact: GSK Pharma's June quarter profit down 64% on de-stocking
Stockists were holding 17 days' inventory by end of June, which was 23 days lower than May-end stock
 "GST impact: GSK Pharma's June quarter profit down 64% on de-stocking")
GSK Pharma's underperformance to continue
While there are some signs of sales revival, re-rating would require consistent growth
 "GSK Pharma's underperformance to continue")
Govt price controls affect GSK Pharma's results
Company will have to improve volumes, cut costs to overcome impact of lower pricing
 "Govt price controls affect GSK Pharma's results")
